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University as Licensor of Patents
• All patent infringement cases are brought in federal court
• All owners and exclusive licensees must be named parties
• Inventors and tech transfer office as witnesses
– Depositions, trial
• Importance of record-keeping
– Confidentiality agreements
– Invention disclosures
– Lab notebooks, samples, photos, prototypes
– Emails
• Document retention policy
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I wish I hadn’t said that……
• Inventor re: his patent application:  “[W]hy is this not
obvious?”
– Purdue Pharma v. Par Pharma(D.Del. 2009)
• Bill Gates to AOL execs: "How much do we need to 
pay you to screw Netscape?"
Key Considerations for License Agreements
• How is infringement monitored and reported?
• What is the process for deciding to sue?
• Who controls litigation strategy?
• Who pays?
• How is counsel selected?  One firm representing all?
– Duty of loyalty and conflicts of interest
• Any change to royalties during litigation?
• Who decides settlement?
• How are recoveries split?
Hatch-Waxman Act Patent Litigation Statistics
Source:  RBC Capital Markets Industry Comment, January 15,2010
• Patent challenges remain on the rise with a record 65 new 
lawsuits in 2009, up from 51 in 2008 and more than 
double the number 3 years ago
• For cases that have gone to trial, generics won 48%
• When settlements are included, success rate increases to 
76% for generics
• More than half of cases are settled or dropped
• Top 3 courts by volume—NJ, DE, SDNY—accounted for 
70% of all decisions
KSR, Int’l Co. v. Teleflex, Inc., 127 S.Ct. 1727 (2007)
U.S. Supreme Court Refines What’s Obvious
• Three categories of post-KSRpharma cases:
– Stereoisomeric purification
– New chemical entities
– Derived from the modification of structurally 
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similar compounds
– Pharmaceutical formulations
MOTIVATION FOR PURIFICATION OF 
STEREOISOMERS AND OTHER MIXTURES
• Two factors for determining obviousness of a purified 
active ingredient:
– Unexpected properties of the isolated 
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stereoisomer
– Amount of experimentation required for the 
separation and purification of the desired 
stereoisomer
CASE STUDY - LEXAPRO®
Forest Labs. v. Ivax, 501 F.3d 1263 (Fed. Cir. 2007)
Lexapro® Prior Art
S-citalopram S/R-citalopram
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• Purified S-enantiomer held NONOBVIOUS:
– S-enantiomer unexpectedly had twice the activity of the racemic 
mixture (i.e., the R-enantiomer had no therapeutic activity)
– The stereoisomers were difficult to separate as evidenced by the 
failure of others to do so
CASE STUDY - PLAVIX®
Sanofi v. Apotex, 550 F.3d 1075 (Fed. Cir. 2008)
• Prior art disclosed that the racemic mixture exhibited both therapeutic 
activity and neurotoxicity
Plavix® Prior Art
D-clopidogrel 
bisulfate
D/L-clopidogrel 
bisulfate
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• Plavix® held NONOBVIOUS:
– Unexpectedly, dextrorotatory enantiomer exhibited only therapeutic activity 
whereas the levorotatory enantiomer exhibited only neurotoxicity
– Separation technique was not simple or routine
– Reaction of sulfuric acid with active ingredients to form bisulfate salts was 
known to cause racemization (i.e., prior art taught away)
MOTIVATION TO PURIFY MAY COME FROM 
STRUCTURALLY SIMILAR COMPOUNDS
• Prior art also taught that in enalapril, a structurally similar 
compound, the SSS isomer had 700 times the therapeutic 
Altace® (ramipril) Prior Art
[SS]SSS isomer Mixture of [SS]SSS and [SS]SSR isomers
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activity as the SSR isomer
• Altace® held OBVIOUS:
– POSITA would expect the [SS]SSS isomer to have higher activity than 
the [SS]SSR isomer given the knowledge of greater activity of the SSS 
isomer in enalapril
– Separation technique was known and routine
Aventis v. Lupin, 499 F.3d 1293 (Fed. Cir. 2007)
NEW CHEMICAL ENTITIES – MODIFICATION OF 
STRUCTURALLY SIMILAR COMPOUNDS
• CAFC has explicitly held that KSR did not change its prior 
analysis with respect to new chemical entities
• Obviousness still requires that the prior art would have 
suggested making or motivated a POSITA to make the 
specific modifications necessary to achieve the claimed 
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invention
NEW CHEMICAL ENTITIES
• Obviousness of new chemical entities made from the 
modification of a structurally similar compound requires:
– Motivation to select the lead compound
• How many viable alternative lead compounds exist?
– Motivation to modify the lead compound to achieve the claimed 
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compound
• Did the modification of the lead compound produce a compound with 
expected properties?
• Was the modification simple and accomplished by standard techniques?
MOTIVATION TO SELECT A LEAD COMPOUND
Takeda v.Alphapharm,492 F.3d 1350 (Fed. Cir. 2007)
C H
Actos® (pioglitazone) Lead Compound in prior art
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CH2CH2 NH3C CH2CH2
• Claimed invention requires two modifications:
– Substitution of ethyl for methyl; AND
– Relocation of the ethyl group from the α-position to the β-
position of the pyridine ring
ACTOS® WAS HELD NONOBVIOUS
• There was no motivation to select the lead compound
– There were at least three other compounds in the prior art with 
properties superior to the lead compound
• Prior art taught away from starting with the lead 
compound
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– Lead compound was known to cause weight gain, which would 
be undesirable for diabetics being treated with Actos®
• Unlike the lead compound, Actos® was unexpectedly non-
toxic
MOTIVATION TO MODIFY LEAD COMPOUND
Eisai v. Dr. Reddy’s, 520 F.3d 1353 (Fed. Cir. 2008)
Aciphex® 
(rabeprazole)
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• Aciphex® held NONOBVIOUS because the desirable 
lipophilic properties of the lead compound was attributed to 
the -CF3 group.  Thus, a POSITA would not be motivated to 
alter the -CF3 group.
Lead Compound 
(lansoprazole)
NEW CHEMICAL ENTITIES -
UNEXPECTED PROPERTIES
AND COMPLICATED DEVELOPMENT
PATHWAYS
• Topomax® (topiramate) was held NONOBVIOUS
– Drug was initially studied for its antidiabetic properties but was found 
to be an effective anticonvulsive drug (secondary consideration of 
nonobviousness)
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– POSITA would not have chosen the starting material used by the 
inventor to synthesize topiramate
– The number of possible synthetic routes from the starting material to 
the claimed compound were numerous, “not the small and finite 
number of alternatives that KSR suggested might support an inference 
of obviousness”
PHARMACEUTICAL FORMULATIONS
• Formulations may be more likely to be found obvious 
where known components or features of the formulations 
are used to provide predictable solutions to known 
problems
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NORVASC® (AMLODIPINE BESYLATE)
Pfizer v. Apotex, 480 F.3d 1348 (Fed. Cir. 2007)
• The prior art references disclosed (1) other amlodipine 
salts and (2) that besylate salts were widely used in the 
pharmaceutical industry
• Norvasc® held OBVIOUS:
– POSITA would have been motivated to make a besylate salt 
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because of their widespread use in pharmaceuticals
– Accordingly, POSITA would have had a reasonable expectation 
of formulating a besylate composition with the desired 
therapeutic activity
OBVIOUSNESS BASED ON EVIDENCE FROM FDA 
FILINGS
• Litigation surrounding Norvasc® demonstrates that your 
competitors will continue to seek evidence of obviousness 
from your statements made in FDA filings
– Pfizer stated to the FDA that prior besylate compounds 
approved by the FDA had worked for the same purpose as 
Pfizer’s besylate salt
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– CAFC gave weight to this evidence
• PROCEED WITH CAUTION
FORMULATIONS - OMEPRAZOLE
In re Omeprazole, 536 F.3d 1361 (Fed. Cir. 2008)
• Claimed Invention
– Enteric-coated omeprazole having a water-soluble subcoating, 
which was necessary to eliminate undesired reactivity between 
the enteric coating and omeprazole
• Prior Art
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– Disclosed enteric-coated omeprazole
– Disclosed the use of subcoatings in pharmaceutical 
formulations
OMEPRAZOLE FORMULATION
• Formulation was held NONOBVIOUS:
– Because the prior art did not teach the reactivity problem 
between the enteric coating and omeprazole, a POSITA would 
not have appreciated the need to include the subcoating
– Variety of other solutions were available to POSITA other than 
using a subcoating (i.e., the number of solutions was not finite)
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– POSITA would not have used a water-soluble subcoating given 
the desire to deliver omeprazole to the small intestine rather 
than the stomach
FORMULATIONS – PK LIMITATIONS
Abbot v. Sandoz, 536 F.3d 1361 (Fed. Cir. 2008)
• Claimed Invention
– Extended release clarithromycin with a PK profile
• Prior Art
– Disclosed extended release erythromycin formulations
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– Disclosed extended release azithromycin formulations and their 
PK profiles
– Disclosed extended release clarithromycin as an alginate salt
FORMULATIONS – PK LIMITATIONS
Abbot v. Sandoz, 536 F.3d 1361 (Fed. Cir. 2008)
• Clarithromycin formulation held NONOBVIOUS:
– Claimed PK limitations were not disclosed in any of the prior art 
references
– Claimed invention was not “obvious to try” because the 
bioavailability of azithromycin was substantially different from 
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clarithromycin
– Formulation of extended release clarithromycin with the 
desired PK limitations was not routine experimentation
PRACTICE SUGGESTIONS IN VIEW OF KSR
• For improvement inventions, incorporate claim limitations 
that result from unpredictable experimentation
– E.g., PK parameters, dissolution rates, fed vs. fasted 
bioavailability, etc.
• Adequately document any difficulties in formulating the 
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compositions and synthesizing or purifying the active 
ingredients
PRACTICE SUGGESTIONS IN VIEW OF KSR
• Base claims on compounds that have unexpected 
properties over prior art compounds
• Analyze the prior art in advance of patenting to assess 
viable claims for the protection of important products
• Beware of making statements during other regulatory 
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proceedings that may jeopardize the validity of your 
patent
